文献速递新发突发、热带与寄生虫病

卢旺达南部2010至2023年恶性疟原虫氯喹耐药标志物pfcrt K76T与pfaat1 S258L的流行率

Prevalence of Plasmodium falciparum Drug Resistance Markers pfcrt K76T and pfaat1 S258L in Southern Rwanda, 2010 to 2023.
PubMed 文献 · J Infect Dis · 2025-01-01

该研究在卢旺达南部Huye区2010至2023年间的606份恶性疟原虫阳性血样中检测pfcrt K76T和pfaat1 S258L。pfcrt K76T流行率从2010年76%降至2018年18%后维持在约25%,pfaat1 S258L保持固定或近固定。pfk13 R561H与pfcrt K76T相关。

要点

  • pfcrt K76T流行率从2010年76%(95%CI 68%-83%)降至2018年18%(95%CI 11%-25%),之后维持在约25%。
  • pfaat1 S258L在Huye区保持固定或近固定。
  • 青蒿素耐药标志物pfk13 R561H与pfcrt K76T相关(P=0.02)。

核心结论

  • 停用氯喹20年后pfcrt K76T仍持续存在,提示持续的药物选择或输入。
  • pfaat1 S258L的固定提示该变异在Huye区无重大适应性代价。
  • 卢旺达部分青蒿素耐药增加及分子标志物提示苯芴醇疗效受损。
  • 研究区域的pfcrt和pfaat1特征可能有助于指导青蒿素联用药物的替代选择。

研究设计与样本

  • 研究检测2010、2014、2018、2019和2023年采集的社区儿童和疟疾患者的恶性疟原虫阳性血样,共606份。
  • pfcrt K76T采用限制性片段长度多态性基因分型,pfaat1 S258L采用高分辨率熔解曲线(2010-2019年),2023年样本采用纳米孔测序。

主要发现

  • 606份样本中,pfcrt K76T流行率从2010年76%(95%CI 68%-83%)降至2018年18%(95%CI 11%-25%),此后保持恒定在约25%(P<.001)。
  • 未观察到其他pfcrt标志物。
  • pfaat1 S258L保持固定或近固定。
  • 青蒿素耐药标志物pfk13 R561H与pfcrt K76T相关(P=.02)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In many countries in Sub-Saharan Africa, the Plasmodium falciparum chloroquine resistance marker pfcrt K76T disappeared within a decade after use of chloroquine ceased. pfaat1 S258L has recently been implicated as another chloroquine resistance marker. Both genes may affect parasite susceptibility to partner drugs in artemisinin-based combination therapy. Rwanda abolished chloroquine use in 2001, and since 2006 the first-line antimalarial is artemether-lumefantrine. However, partial artemisinin resistance emerged in the region. We assessed the prevalence of pfcrt and pfaat1 markers in Huye district between 2010 and 2023, following trends and updating the status in southern Rwanda. METHODS: P. falciparum-positive blood samples from community children and malaria patients collected in 2010, 2014, 2018, 2019, and 2023 were examined. pfcrt K76T was genotyped by restriction fragment length polymorphism, and pfaat1 S258L by high-resolution melting curve (2010-2019). Samples from 2023 were subjected to nanopore sequencing. RESULTS: In 606 samples, pfcrt K76T prevalence declined from 76% (95% confidence interval [CI], 68%-83%) to 18% (95% CI, 11%-25%) between 2010 and 2018 but remained constant since at around 25% (P < .001). No other pfcrt markers were observed. pfaat1 S258L has remained at or near fixation. The artemisinin resistance marker pfk13 R561H was associated with pfcrt K76T (P = .02). DISCUSSION: The persistence of pfcrt K76T 20 years after abolishing chloroquine use indicates ongoing drug selection or importation. The fixation of pfaat1 S258L argues against a major fitness cost of this variant in Huye. Increases in partial artemisinin resistance in Rwanda and molecular markers indicate compromised lumefantrine efficacy. The observed pfcrt and pfaat1 signatures in the study area might be of use in guiding artemisinin partner drug alternatives.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Schallenberg E, van Loon W, Mbarushimana D, et al. Prevalence of Plasmodium falciparum Drug Resistance Markers pfcrt K76T and pfaat1 S258L in Southern Rwanda, 2010 to 2023. J Infect Dis. 2025. PMID: 39936828. doi:10.1093/infdis/jiaf068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。